Genentech Releases SMA Community Letter with Evrysdi (risdiplam) Updates

Genentech, a member of the Roche Group, logo

Our partners at Genentech recently provided an SMA Community Letter regarding Evrysdi® (risdiplam) and their clinical development program.

Visit this link to learn more.

Do you like what you're reading?

Help make a difference in the lives of people affected by spinal muscular atrophy.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top